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Abstract 
Background: To determine the diagnostic accuracy 
of triple assessment in diagnosis of breast cancer in 
women more than 40 years keeping histopathology 
as gold standard. 
Methods: In this cross sectional study, women with 
a breast lump or change in the texture of breast with 
an age range of  40-70 years   were included. Detailed 
physical and breast examination and mammography 
followed by FNAC were performed. Mammography 
of breast consists of two standard views , i.e.,  lateral 
oblique (MLO) and a craniocaudal view (CC). 
Sensitivity, specificity, positive predictive value and 
negative  predictive value and  accuracy of triple 
assessment were calculated. 
Results: There were 49.5% patients who were 
labelled as malignant. Mammogram showed 69.7% 
as malignant. On FNAC 64.8%  were labelled as 
malignant. Results of triple assessment showed  
72.4% as malignant. Histopathology results showed  
73.3% as malignant, thus showing that in overall 
study population 71.5%  were true positives, 25.7%  
were true negatives, 1%  were false positives and 
2.0%  were false negatives.   The study findings 
revealed that sensitivity, specificity, PPV, NPV and 
accuracy of triple assessment in diagnosing breast 
cancer is 97.4%, 96.4%, 98.7%, 93.1% and 97.2% 
respectively. 
Conclusion: Triple assessment allows detection of 
malignancy in palpable breast lumps with 
acceptable sensitivity, specificity, positive predictive 
value, negative predictive value and accuracy.  
Key Words:  Breast cancer, Triple assessment, 
Mammography, Fine needle aspiration cytology 
 
Introduction 
Breast malignancy is one of the major health issues 
affecting women all over the globe. Globally, it is the 
second most common malignancy.1 In Pakistan; it is 
the commonest malignancy in women with a 
prevalence of 34.6%.2  A prompt and accurate 
diagnosis followed by timely intervention can be 
lifesaving in managing patients with breast 
malignancy.1 There are various non-invasive imaging 
modalities for diagnosing breast lesions e.g. 
ultrasonography, mammography, MRI, Doppler 
scanning, contrast enhanced ultrasound, etc but alone 
none of these is reliable.1 Their cost and availability 
also limit their use. There are three pathological 
procedures for diagnosing breast cancer , i.e., fine 
needle aspiration cytology, core needle biopsy and 
surgical biopsy.3 FNAC has an advantage over core 
needle biopsy as it is more cost effective and both have 
comparable predictive values.3  FNAc is minimally 
invasive causing pain similar to prick for blood 
sampling. 
Open/surgical biopsy is regarded as a gold standard 
in diagnosing breast cancer. It is invasive , time 
consuming, associated with significant patient anxiety 
and exposes patient to more than one surgical 
procedure.1 Open biopsy  is unlikely to be an initial 
diagnostic approach, unless percutaneous or image-
guided biopsy is not possible. It may become 
necessary to further investigate discordant findings.4-6 
Major disadvantages of FNAc is its inability to 
distinguish between CIS (carcinoma in situ) and 
invasive malignancy along with a high rate of 
insufficient samples.7 Hence it is necessary that a 
diagnostic tool be employed for pre-operative 
diagnosis of breast cancer which is least invasive, cost 
effective and readily available with accuracy 
comparable to conventional surgical biopsy.1 
A combination of three modalities called as triple 
assessment is currently employed in diagnosing all the 
breast lesions. It includes physical examination, 
radiological imaging (mammography) and pathology 
(FNAC).8,9 It is a simple and affordable test with 
modalities used being non-invasive or minimally 
invasive. It is performed on OPD basis and requires no 
hospitalization.8 Furthermore, it is a readily available 
and reliable diagnostic tool with a sensitivity of 93% 
and specificity of 95.2%.10 
 
Patients and Methods 
In this cross sectional study, conducted in Department 
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of Radiology, RMC and Allied Hospitals, Rawalpindi, 
in collaboration with Pathology department of the 
same hospital, women with a breast lump or change in 
the texture of breast with an age range of  40-70 years   
were included. Women with breast abscess, anti-
bioma, mastitis, infected cyst, mammary fistula  and 
diagnosed cases of malignancy were excluded. Sample 
size (n=105) was calculated by using sensitivity 
specificity sample size calculator taking  
sensitivity93%, absolute precision 7%,specificity 95.2%, 
absolute precision 4.8%, expected prevalence 34.6%  
and confidence level as  95%.10 Mammography of 
breast consists of two standard views , i.e.,  lateral 
oblique (MLO) and a craniocaudal view (CC). The 
lateral oblique view was done by angulating the tube 
at 45 degrees to the horizontal. Depending on the 
patients build  tube angulations was changed by 30 to 
60 degrees to the horizontal. For adequate 
visualization, breast was lifted and compression was 
applied in order to spread the breast tissue evenly 
between the film holder and compression plates. No 
skin folds were superimposed on the breast. The 
craniocaudal view (CC) demonstrated subareolar, 
medial and lateral portions of breast. All the patients 
were sent to pathology department for FNAC . The 
results of physical examination, mammography and 
FNAC were classified as benign and malignant and 
compared to histopathological report of biopsies from 
specimens obtained at time of definitive surgery. A 
2x2 table was used to calculate sensitivity, specificity, 
PPV, NPV and accuracy of triple assessment for 
diagnosing breast cancer using the findings of 
histopathology as gold standard.   
 
Table 1: Two × Two Table 
Triple assessment 
(Physical exam, 
Mammography, 
FNAC) 
Histopathology Total 
Malignant Benign   
Malignant True 
Positive (a) 
True 
Negative (b) 
a + b 
Benign False 
Negative (c) 
False 
Positive (d) 
c + d 
Total a + c b + d a + b + c 
+d 
 
Results 
 Mean age of patients (n=105) was 49.9 years ± 6.7 , 
with a range of 41 years to 69 years . On physical 
examination  49.5%  of patients were labeled as 
malignant . Mammogram results showed there were  
65.7%  patients who were labeled as malignant  . 
FNAC results showed there were 64.8%  patients who 
were labeled as malignant  ( Table 2). Results of triple 
assessment showed that there were 72.4% of patients 
who were labeled as malignant . Histopathology 
results showed that 73.3%  of patients were 
malignant(Table 3). 2 x 2 tables showed the numbers 
of cases who were malignant on triple assessment scan 
and were also malignant on Histopathology (true 
positives), who were malignant on triple assessment 
scan positive but were benign on histopathology (false 
positives), who were benign on triple assessment scan 
but were malignant on histopathology (false negatives) 
and who were benign on triple assessment scan and 
were also benign on histopathology (true negatives).  
Our study results showed that in overall study 
population 71.5%  were true positives, 25.7%  were 
true negatives, 1% were false positives and 2.0%  were 
false negatives (Table 4). Results depicted that 
sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and accuracy of triple 
assessment in diagnosing breast cancer is 97.4%, 
96.4%, 98.7%, 93.1% and 97.2% respectively.  
 
Table 2: Results of Physical Examination, 
Mammogram and  FNAC 
Modality Benign (%) Malignant (%) 
Physical examination 50.5 49.5 
Mammography 34.3 65.7 
FNAc 64.8 35.2 
 
Table 3: Results of Triple Assessment & 
Histopathology 
Modality Benign (%) Malignant (%) 
Triple assessment 27.6 72.4 
Histopathology  26.7 73.3 
 
Table 4:  Cross-tabulation of Triple assessment 
and histopathology results 
 Histopathology   
Triple 
assessmen
t 
Malignant Benign total 
Malignant 75(True 
positives)  
1(False positives) 76 
Benign 2(False 
negatives) 
27(True 
Negatives) 
29 
Total 77 28 105 
Sensitivity: 97.4%, Specificity: 96.4%, Positive Predictive Value: 
98.7%, Negative Predictive Value: 93.1%, Over all Accuracy: 97.2% 
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Discussion 
 A definite diagnosis of a woman presenting with 
breast lump is highly crucial for the surgeon in order 
to decide final treatment thus saving the female from 
unnecessary burden of psychosocial, physical and 
emotional trauma.11, 12 Although majority of breast 
lumps in women of 20-50 years of age group are 
benign, but still it is very important to exclude 
malignancy.13 A combination of three tests/ modalities 
is devised to approach women presenting with breast 
problems. It is called as triple assessment or triple test 
and includes clinical examination, radiological 
imaging (mammography) and pathology. These 
modalities when employed alone give variable results 
but together they have sensitivity of 99%.14 If any one 
out of three components is positive, then triple 
assessment is also considered positive but all the three 
components should be negative for triple assessment 
to be negative. Regarding pathology, FNAC is taken as 
a component of triple assessment rather than core 
needle biopsy since it is minimally invasive and cost 
effective, moreover in settings where a trained 
cytopathologist is available it has predictive value 
comparable to core needle biopsy.3,14 Breast of young 
patients are very sensitive to radiation but if there is 
high suspicion of malignancy along with a strong 
family history, mammography can be done.15 On 
mammography most of breast cancers appear as 
spiculated masses, others being masses with irregular 
margins, oval, round lobulated lesions, well defined 
masses or areas of architectural distortion.16 
Ghimire B. et al showed that triple assessment had an 
accuracy of 98% with sensitivity of 100% and 
specificity being 95.2%.Morris KT, et al also evaluated 
the accuracy of triple assessment by devising a 
modified triple assessment score.18 113 patients were 
included in the study. All the benign lesions were 
given a score of 1, suspicious lesions 2, and malignant 
lesions 3 on each modality. Sum of these 3 score gave 
the final score. Results were then correlated with 
biopsy. It was found that triple assessment had an 
accuracy of 100%. They further suggested that lesions 
having less than four score are benign, those with five 
score should undergo biopsy and those with six and 
higher score should undergo definitive treatment. This 
approach thus avoided unnecessary biopsies. 
Morris A, et al also evaluated accuracy of triple 
assessment in evaluating breast lumps to avoid 
unnecessary biopsies.19 The study included 261 female 
patients. All the benign lesions were given a score of 1, 
suspicious lesions 2, and malignant lesions 3 on each 
modality. Sum of these 3 score gave the final score. 
Results were then correlated with biopsy. It was found 
that triple assessment had an accuracy of 100%.  
Mansoor I, et al conducted a similar study on non-
diagnostic FNACs of palpable breast masses and 
compared the results with the available literature.20 All 
malignant cases had scores of above 6 except one that 
scored 5. Two benign cases had scores of 1 and 3. They 
concluded that triple assessment can be used to 
achieve diagnostic accuracy for breast FNACs and 
management of breast lumps. 
Kachewar SS, et al conducted a prospective study to 
calculate accuracy of triple assessment in diagnosing 
breast lumps.21 Triple assessment was done in 200 
cases out of 225 FNACs.  Out of 124 cases, 123 had 
concordant triple assessment score and 3 discordant. 
Of 62 malignant cases on FNAC, only one had 
discordant triple assessment score. Biopsy was done 
only in seventy patients, out of which forty two were 
malignant and twenty eight benign. This gave triple 
assessment a sensitivity of 97.44% and specificity of 
100%. 
Kaufman Z, et al also conducted a similar study 
determining accuracy of triple assessment.22 The study 
included 234 patients which were labelled as benign, 
Figure 2:Craniocaudal 
view of breast showing  
well circumscribed 
lobulated mass with 
coarse calcification 
typical of fibroadenoma 
Figure 1:Craniocaudal 
view of breast showing 
well defined rounded 
radio-opacity with coarse 
calcification suggesting a 
benign lesion 
Figure 3:Mediolateral oblique and craniocaudal view of 
breast shows an ill defined, irregular spiculated mass in 
upper outer quadrant of breast causing architectural 
distortion 
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suspicious and malignant on triple assessment 
followed by histopathology. The sensitivity and 
specificity of the each test was less than triple 
assessment which turned out to be 100% and 57% 
respectively. They concluded that breast lesions can be 
diagnosed with accuracy by triple assessment, thus 
obviating the need for invasive procedure (open 
biopsy). 
Ahmed I, et al also determined the accuracy of triple 
assessment in characterizing breast lesions.23 They 
scored results of triple assessment as concordant and 
non-concordant. If all elements were either benign or 
malignant then findings were considered as 
concordant and non-concordant if the elements were 
neither all malignant nor benign. The study concluded 
that triple assessment is less time consuming, 
minimally invasive and cheap, however, it should only 
be employed in settings where good imaging 
modalities and trained staff are available.A study by 
Salami N, et al concluded that triple assessment can be 
used with high diagnostic accuracy to evaluate breast 
lumps. 24 Kharkwal S, et al conducted a prospective 
study to calculate accuracy of triple assessment in 
diagnosing breast cancer.25 It was found that all these 
modalities had less accuracy when employed alone 
but in combination triple assessment gave 100% 
sensitivity and specificity.  
Conclusion 
Triple assessment allows detection of malignancy in 
palpable breast lumps with sensitivity, specificity, 
PPV, NPV and accuracy of 97.4%, 96.4%, 98.7%, 93.1% 
and 97.2% respectively.  
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